Intravenous administration of glial cell line‐derived neurotrophic factor gene‐modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in the adult rat

Intravenous administration of human mesenchymal stem cells (hMSCs) prepared from adult bone marrow has been reported to ameliorate functional deficits after cerebral artery occlusion in rats. Several hypotheses to account for these therapeutic effects have been suggested, and current thinking is that neuroprotection rather than neurogenesis is responsible. To enhance the therapeutic benefits of hMSCs potentially, we transfected hMSCs with the glial cell line‐derived neurotrophic factor (GDNF) gene using a fiber‐mutant F/RGD adenovirus vector and investigated whether GDNF gene‐modified hMSCs (GDNF‐hMSCs) could contribute to functional recovery in a rat permanent middle cerebral artery occlusion (MCAO) model. We induced MCAO by using intraluminal vascular occlusion, and GDNF‐hMSCs were intravenously infused into the rats 3 hr later. MRI and behavioral analyses revealed that rats receiving GDNF‐hMSCs or hMSCs exhibited increased recovery from ischemia compared with the control group, but the effect was greater in the GDNF‐hMSC group. Thus, these results suggest that intravenous administration of hMSCs transfected with the GDNF gene using a fiber‐mutant adenovirus vector may be useful in the cerebral ischemia and may represent a new strategy for the treatment of stroke. © 2006 Wiley‐Liss, Inc.

[1]  K. Houkin,et al.  Intravenous infusion of immortalized human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat , 2006, Experimental Neurology.

[2]  K. Houkin,et al.  I.v. infusion of brain-derived neurotrophic factor gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat , 2005, Neuroscience.

[3]  K. Houkin,et al.  A therapeutic window for intravenous administration of autologous bone marrow after cerebral ischemia in adult rats , 2004, Brain Research.

[4]  K. Houkin,et al.  BDNF gene-modified mesenchymal stem cells promote functional recovery and reduce infarct size in the rat middle cerebral artery occlusion model. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  K. Houkin,et al.  Telomerized human multipotent mesenchymal cells can differentiate into hematopoietic and cobblestone area-supporting cells. , 2003, Experimental hematology.

[6]  H. Tsuda,et al.  Efficient BMP2 gene transfer and bone formation of mesenchymal stem cells by a fiber-mutant adenoviral vector. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  Yi Li,et al.  Ischemic rat brain extracts induce human marrow stromal cell growth factor production , 2002, Neuropathology : official journal of the Japanese Society of Neuropathology.

[8]  I. Date,et al.  Neuroprotective and restorative effects of intrastriatal grafting of encapsulated GDNF‐producing cells in a rat model of Parkinson's disease , 2002, Journal of neuroscience research.

[9]  I. Nagano,et al.  Therapeutic time window of adenovirus-mediated GDNF gene transfer after transient middle cerebral artery occlusion in rat , 2002, Brain Research.

[10]  M. Chopp,et al.  Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats , 2001, Journal of the Neurological Sciences.

[11]  S. Kügler,et al.  Adenovirus-Mediated GDNF and CNTF Pretreatment Protects against Striatal Injury Following Transient Middle Cerebral Artery Occlusion in Mice , 2001, Neurobiology of Disease.

[12]  Takeshi Hayashi,et al.  Time dependent amelioration against ischemic brain damage by glial cell line-derived neurotrophic factor after transient middle cerebral artery occlusion in rat , 2001, Brain Research.

[13]  T. Neumann-Haefelin,et al.  Serial MRI after transient focal cerebral ischemia in rats: dynamics of tissue injury, blood-brain barrier damage, and edema formation. , 2000, Stroke.

[14]  M. Matsuzaki,et al.  Angiogenesis Induced by the Implantation of Self-Bone Marrow Cells: A New Material for Therapeutic Angiogenesis , 2000, Cell transplantation.

[15]  M. Murakami,et al.  CTLA4IgG gene delivery prevents autoantibody production and lupus nephritis in MRL/lpr mice. , 2000, Life sciences.

[16]  M. Murakami,et al.  Persistent and secondary adenovirus-mediated hepatic gene expression using adenovirus vector containing CTLA4IgG. , 1998, Human gene therapy.

[17]  S. Gerson,et al.  Phenotypic and functional comparison of cultures of marrow‐derived mesenchymal stem cells (MSCs) and stromal cells , 1998, Journal of cellular physiology.

[18]  Y. Itoyama,et al.  Reduction of ischemic brain injury by topical application of glial cell line-derived neurotrophic factor after permanent middle cerebral artery occlusion in rats. , 1998, Stroke.

[19]  Takeshi Hayashi,et al.  Expression of the glial cell line-derived neurotrophic factor gene in rat brain after transient MCA occlusion , 1997, Brain Research.

[20]  G. Donnan,et al.  Expression of glial cell line-derived neurotrophic factor (GDNF) mRNA following mechanical injury to mouse striatum. , 1997, Neuroreport.

[21]  P. Shabram,et al.  Sensitivity and reproducibility in adenoviral infectious titer determination , 1997, Nature Medicine.

[22]  B. Hoffer,et al.  Glial Cell Line-Derived Neurotrophic Factor Protects against Ischemia-Induced Injury in the Cerebral Cortex , 1997, The Journal of Neuroscience.

[23]  L Li,et al.  Rescue of adult mouse motoneurons from injury-induced cell death by glial cell line-derived neurotrophic factor. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  L. Olson,et al.  Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo , 1995, Nature.

[25]  Q. Yan,et al.  In vivo neurotrophic effects of GDNF on neonatal and adult facial motor neurons , 1995, Nature.

[26]  R. Oppenheim,et al.  Developing motor neurons rescued from programmed and axotomy-induced cell death by GDNF , 1995, Nature.

[27]  R. Vandlen,et al.  Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain , 1995, Nature.

[28]  H. Wakimoto,et al.  Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2. , 1994, Cancer research.

[29]  C. Henderson,et al.  GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. , 1994, Science.

[30]  J. Lile,et al.  GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.

[31]  C. Eaves,et al.  Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. II. Analysis of positive and negative regulators produced by stromal cells within the adherent layer. , 1991, Blood.

[32]  L. Pitts,et al.  Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. , 1986, Stroke.

[33]  K. Kuriyama,et al.  Biochemical-physiology correlations in studies of the γ-aminobutyric acid system , 1968 .

[34]  K. Houkin,et al.  Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  P. Weinstein,et al.  Reversible middle cerebral artery occlusion without craniectomy in rats. , 1989, Stroke.